Who makes Fluvastatin extended release tablet?

Fluvastatin extended release tablet is developed by Beijing Anzhen Hospital.

What development phase is Fluvastatin extended release tablet in?

Fluvastatin extended release tablet is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Fluvastatin extended release tablet

Beijing Anzhen Hospital · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Fluvastatin extended release tablet
Also known as	Lescol XL
Sponsor	Beijing Anzhen Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Bioequivalence Study of Fluvastatin Sodium Extended Release Tablets in Healthy Participants (PHASE1)
Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (PHASE4)
Fluvastatin AmelIorates aTHerosclerosis Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Fluvastatin extended release tablet CI brief — competitive landscape report
Fluvastatin extended release tablet updates RSS · CI watch RSS
Beijing Anzhen Hospital portfolio CI